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Urine hemosiderin: A novel marker to assess the
severity of chronic venous disease
Paolo Zamboni, MD,a Marcello Izzo, MD,a Luisella Fogato, MD,a Sergio Carandina, MD,a and
Vincenzo Lanzara, PhD,b Ferrara, Italy
Objective: Impaired venous drainage in severe chronic venous insufficiency (CVI) leads to microcirculatory overload,
characterized by erythrocyte diapedesis and subsequent extravascular hemolysis, resulting in typical dermal hemosiderin
deposition. We hypothesized that hemosiderin, normally absent, could be present in the urine in CVI.
Methods: The three-phase study included 117 patients with CVI and 12 healthy control subjects, all of whom had
undergone clinical examination and duplex scanning. In phase 1, current methods were used to test urine for hemosiderin
in 61 persons: 12 healthy control subjects, 24 patients with mild CVI (clinical class C1 to C3), and 25 patients with severe
CVI (clinical class C4 to C6). In phase 2, the concentration of urinary hemosiderin was determined in 45 consecutive
patients with CVI, CEAP class 1 to 6. A score of 0 was assigned when typical hemosiderin granules were absent at
microscopic examination, a score of 1 when one to three granules per field were detected; 2 when four to six granules were
detected; and 3 when more than six granules were observed. Phase 3 included 23 patients with CVI (clinical class 2 to 6).
Hemosiderin concentration was determined and a score assigned before patients underwent surgical procedures to correct
primary CVI. Both hemosiderin testing and duplex scanning were repeated after 6 months.
Results: Phase 1: Urine hemosiderin testing to determine presence or absence of CVI in patients with reflux detectable at
duplex scanning yielded the following values: positive predictive value, 96% (95% confidence interval [CI], 86% to 100%);
negative predictive value, 88% (CI, 68% to 97%); sensitivity, 94% (CI, 72% to 99%); specificity, 91% (CI, 83% to 99%); and
diagnostic accuracy, 95% (CI, 86% to 99%). Phase 2: Hemosiderinuria score enabled classification of clinical severity of
CVI. Mean scores, respectively, were clinical class 1, 0.18 0.12; class 2, 0.75 0.47; class 3, 1.67 0.21; class 4, 1.86
0.26; class 5, 2.50  0.28; and class 6, 1.92  0.21 (P < .001). Phase 3: At 6-month follow-up, hemosiderin score was
improved, from 2.48 0.12 preoperatively to 0.78 0.18 postoperatively (P < .0001). A score of 0 or 1 was associated
with successful surgery, whereas a score of 2 or 3 reflected persistence of reflux.
Conclusions: Determination of presence of hemosiderin in the urine is a new, sensitive, cost-effective, noninvasive, and
repeatable test that enables detection of substantial microcirculatory overload in patients with CVI. (J Vasc Surg 2003;
37:132-6.)
Current tests used to differentiate normal from abnor-
mal venous function, eg, duplex scanning, ambulatory ve-
nous pressure, foot volumetry, photoplethysmography,
and air plethysmography, do not enable classification of
clinical severity of chronic venous insufficiency (CVI), be-
cause sensitivity and specificity are unsatisfactory.1-3 Fur-
thermore, clinical stage of disease as defined by section C of
the (CEAP) classification system, does not indicate severity
of venous disease, because many of its components are
relatively static and others use detailed alphabetic designa-
tions. A scoring scheme for disease severity must be quan-
tifiable, with elements that can change in response to
treatment. Accordingly, the American Venous Forum has
proposed a 10-component venous clinical severity score
(VCS) to improve objective assessment of venous dis-
ease.4,5
The ideal test for detecting this common chronic dis-
ease would be cost-effective, noninvasive, and easily repeat-
able, and would detect a marker for CVI in urine or serum.
Impaired venous drainage in severe CVI (clinical class 4
to 6) leads to microcirculatory overload, characterized by
proliferation of small blood vessels with trapping of white
blood cells, and evidence of fibrin cuffs with ulceration.6-8
In addition, stasis favors erythrocyte diapedesis with subse-
quent extravascular hemolysis and dermal hemosiderin
deposition.
We hypothesized that hemosiderin, as in intravascular
hemolytic disease, would be present in urine in such a
model of extravascular hemolysis.9-13 Inasmuch as it is
absent in normal urine, we sought to identify hemosiderin
as a new marker of chronic venous disease.
METHODS
Phase 1: Assessment of hemosiderinuria
Phase 1 included 61 subjects (38 women, 33 men;
mean age, 48), all of whom had undergone clinical exami-
nation and duplex scanning.1 Twelve were healthy medical
students without clinical or duplex scan evidence of CVI
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who served as the control group. Twenty-four were pa-
tients with clinical or duplex scan evidence of mild CVI
(clinical class C1 to C3); nine of these patients had C1
disease without duplex scan evidence of reflux. Twenty-five
were patients with severe CVI (clinical class C4 to C6). The
possibility of a simultaneous intravascular hemolytic condi-
tion was excluded by negative results of blood tests that
included determination of hemochrome, haptoglobin, fer-
ritin, transferrin, iron, and bilirubin concentrations; hemat-
ocrit ratio; and antiglobulin testing (Coombs’ test).9 Cur-
rent methods were used to test for hemosiderinuria in both
patients and control subjects.13
Determination of urinary hemosiderin. Urinary he-
mosiderin was determined in a 10-mL sample of total daily
urine centrifuged at 800g for 10 minutes, for microscopic
examination of urinary sediment. After centrifugation, the
supernatant was poured off and the pellet resuspended in 5
mL of a hemosiderin staining reagent obtained by mixing
equal volumes of 2% potassium ferrocyanide (w/v) and 2%
hydrochloric acid, obtained by diluting 17.5-fold the com-
mercial analytical grade reagent. The sediment was thor-
oughly mixed and allowed to stand for 10 minutes. Tubes
were centrifuged again, the supernatant was siphoned off,
and the stained pellet was resuspended in a minimal volume
of liquid to wet the tube walls and transferred to a micros-
copy slide. A cover slide was applied, and the specimen was
studied at400 magnification. Typical deeply blue-stained
granules indicated a positive test result (Fig 1).9,13
Phase 2: Urine hemosiderin score
Phase 2 included 45 consecutive patients (13 men, 32
women; mean age, 58 years) with CVI. In all patients the
diagnosis was confirmed with complete duplex scanning of
both legs. According to CEAP classification, CVI was
scored as clinical class 1, with no evidence of reflux at
duplex scanning, in 11 patients; class 2 in 4 patients; class 3
in 6; class 4 in 7; class 5 in 4; and class 6 in 13.
Urinary hemosiderin was detected according to the
methods described above. A score of 0 was assigned in the
absence of typical granules; a score of 1 when one to three
granules per field were detected; 2 when four to six granules
were detected; and 3 when more than six granules were
observed. Scores were then compared with clinical disease
class.
The concentration of hemosiderin granules in the urine
sediment was not assessed. Hemosiderin score reflects the
overall number of hemosiderin granules found in the uri-
nary sediment, which was not modified by changing the
volume in which the sediment was resuspended.
Phase 3: Urinary hemosiderin at postoperative
follow-up
Phase 3 included 23 consecutive patients (11 men, 12
women; mean age, 54 years) scheduled to undergo surgical
correction of monolateral primary superficial CVI con-
firmed at duplex scanning. Three patients had clinical class
2 disease; 4, class 3 disease; 6, class 4 disease; 3, class 5
disease; and 7, class 6 disease. Hemodynamic correction
procedures for reflux elimination were carried out, sparing
the saphenous vein14,15 Urine hemosiderin assessment and
duplex scanning were repeated at 6-month follow-up
Statistical analysis
Data are expressed as mean SE. Statistical assessment
of distribution of test results between clinical classes of
disease was performed with the Kruskal-Wallis test. Differ-
ences in preoperative and postoperative urine hemosiderin
scores were tested for significance with the Wilcoxon and
Mann-Whitney U tests. P .05 was considered significant.
Positive predictive value (PPV), negative predictive value
(NPV), sensitivity, specificity, and diagnostic accuracy of
the test were assessed, using the 95% confidence interval
(CI) when appropriate.
RESULTS
Phase 1. Urine hemosiderin test results were negative
in all control subjects, but were positive in 7 of 24 (29%)
patients with mild CVI (clinical class 1 to 3) and 23 of 25
(92%) patients with severe CVI (clinical class 4 to 6) (P 
.0001, Kruskal-Wallis test) (Fig 2).
In assessing for the presence or absence of CVI in
patients with reflux detected at duplex scanning, the test
demonstrated PPV of 96% (CI, 86% to 100%); NPV, 88%
(CI, 68% to 97%); sensitivity, 94% (CI, 83% to 99%);
specificity, 91% (CI, 72% to 99%); and diagnostic accuracy,
95% (CI, 86% to 99%).
In contrast, according to CEAP clinical criteria, which
include simple telangiectasia (class 1), PPV was 100%;
NPV, 52% (CI, 31% to 73%); sensitivity, 71% (CI, 55% to
84%); specificity, 100%; and diagnostic accuracy, 78% (CI,
64% to 88%).
Phase 2. The proposed score based on urine hemo-
siderin concentration enabled classification of CVI accord-
ing to clinical severity. Mean score in clinical class 1 was
0.18  0.12; in class 2, 0.75  0.47; in class 3, 1.67 
0.21; in class 4, 1.86 0.26; in class 5, 2.50 0.28; and in
class 6, 1.92  0.21 (P  .001) (Fig 3).
Fig 1. A typical deeply blue-stained hemosiderin granule in the
urine of a patient with chronic venous insufficiency (magnification,
400).
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Phase 3. Six-month follow-up demonstrated signifi-
cant improvement in the hemosiderin score, from 2.48 
0.12 preoperatively to 0.78  0.18 postoperatively (P 
.0001). This corresponds to surgical outcome as assessed at
clinical examination and duplex scanning.
The score worsened or did not change in only two
patients. In one, duplex scans revealed saphenofemoral
recurrence of disease. In the other patient, superficial ve-
nous surgery was performed in the presence of coexisting
deep reflux, which persisted at duplex scanning 6 months
later.
DISCUSSION
Chronic venous stasis is indicative of erythrocyte diape-
desis and dermal ferritin deposition as a result of extravas-
cular hemoglobin catabolism. Subsequently, the increasing
overload of iron changes the structure of ferritin to hemo-
siderin.9-13,16-19 It is presumed that the hemosiderin stored
in the interstitial matrix partially drains through the lym-
phatic vessels and reaches the circulatory system through
the thoracic duct.
The kidneys have a fundamental role in iron metabo-
lism; however, hemosiderin cannot be filtered because of its
high molecular weight. Hemosiderin accumulates in the
cells of the tubular epithelium and is only secondarily
excreted when such cells are shed into the urine.12 This
mechanism seems to apply to our findings.
There is lack of a true standard between investigations
used in patients with CVI. The CEAP classification, al-
though somewhat rigid, is still the best method for defining
the clinical severity of CVI.1
Recently the system was improved with the introduc-
tion of the VCS score, which is quantifiable and gradable,
with elements that can change in response to clinical vari-
ations resulting from treatment or natural progression of
disease.4,5 However, VCS scores also show small but sig-
nificant intraobserver and interobserver variability, which
could affect their reliability.5 We believe the urine hemo-
siderin test to be a valuable tool to be used in addition to
clinical assessment, especially in differentiating between
class 1 and 2 and class 3 and 4 CVI, in which both
intraobserver and interobserver variation seems to occur
more frequently.5
The main finding of our study is that positive results of
the urine hemosiderin test enable differentiation of healthy
subjects from patients with CVI and duplex scan–detect-
able reflux, with significant PPV, NPV, sensitivity, specific-
ity, and accuracy levels. In addition, when the test is used in
healthy subjects and patients with CVI, including those
with class 1 disease without detectable reflux, it almost
always demonstrates correct values for PPV and specificity
but less accurate values for NPV, sensibility, and diagnostic
accuracy, because of a higher number of false negative
results.
This raises the question of whether most patients with
class 1 disease should be considered to have CVI or a
different pathologic condition, often coexistent, mainly
cosmetic, but with unrelated pathogenesis, pathophysio-
logic features, and prognosis. Usually in such patients ve-
nous investigations do not demonstrate any venous reflux
or obstruction, and the urine hemosiderin marker is not
positive.
Moreover, clinical classification of CVI as class 1 or 2 in
patients with considerable dilatation of the venular system
is sometimes difficult. In such cases, it could be proposed
that clinical class 2 be assigned only to disease in patients
with positive hemosiderin test results, drastically reducing
CEAP and VCS score interobserver and intraobserver vari-
ability.
Results of the proposed test appear to be consistently
positive in the more severe cases, and, when positive early
during clinical evolution of the disease, might precede by
years the dermal accumulation of visible hemosiderin de-
posits. This hypothesis remains to be proved in a rigorous
longitudinal test.
In addition, results of the proposed hemosiderin test
may lead to modification of the clinical management of
uncomplicated varicose veins. For example, in patients with
varicose veins and negative urine hemosiderin test results
treatment could consist of use of elastic stockings along
with comprehensive follow-up.
Fig 2. Urine hemosiderin test in healthy control subjects and
patients with chronic venous insufficiency. Test results are always
negative in healthy subjects and are more likely positive with
increasing clinical severity of disease (P  .001).
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The patient who prefers surgical treatment should be
made aware that the main purpose of the procedure is
cosmetic. Surgery could be reserved for patients with C2
disease with a positive test result, to prevent progression of
the disease to class C4 to C6.
Phase 2 of our study demonstrates how the proposed
test scoring system enables rapid, albeit rough, quantifica-
tion of the concentration of hemosiderin in the urinary
sediment. In addition, the scoring system enables differen-
tiation of the clinical classes of CVI (Fig 3). It is curious that
the hemosiderin score was higher in clinical class 5 disease
than in clinical class 6. Recently, nitric oxide was found to
be highly concentrated in patients with healed ulcer-
ations.20 This could be related to the natural drainage of
toxic agents through the ulcers, with consequent reduction
in renal hemosiderin elimination.
Finally, the proposed scoring system is useful for pa-
tient follow-up after surgery. Reduction of venous overload
contributed to significant improvement in the hemosider-
inuria score within 6 months (Fig 4). This finding could
represent a possible future rapid, economic, and cost-effec-
tive tool for monitoring patient outcome after surgery, to
complement the clinical CEAP or VCS score at office
evaluation. For example, in patients with preoperative clin-
ical class 4 or 5 disease, with irreversible skin damage, CVI
is difficult to reclassify on the basis of physical examination
alone and, despite a successful surgical outcome, often
must be reevaluated with duplex scanning or other hemo-
dynamic tests.
According to our findings, instrumental investigations
could be reserved for patients with urine hemosiderin
scores of 2 or 3. In our survey, when the score was 0 or 1 (ie,
trace amounts of hemosiderin), duplex scans were always
negative for reflux. Moreover, in phases 1 and 2, a score of
0 or trace amounts of hemosiderin in urine was always
associated with normal venous function or mild disease. In
contrast, in the two patients with unchanged or worse
postoperative scores, duplex scans revealed recurrence of
disease and concomitant deep reflux, respectively (Fig 4).
In conclusion, the hemosiderin test is a new, noninva-
sive, repeatable, and cost-effective method for classifying
chronic venous disease, and further studies are warranted.
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